story of the week
Abemaciclib Effective as a Single Agent in Refractory HR+/HER2− Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
MONARCH 1, a Phase 2 Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients With Refractory HR+/HER2- Metastatic Breast Cancer
Clin. Cancer Res 2017 May 22;[EPub Ahead of Print], MN Dickler, S Tolaney, HS Rugo, J Cortés, V Dieras, DA Patt, H Wildiers, CA Hudis, JA O'Shaughnessy, E Zamora, D Yardley, M Frenzel, AG Koustenis, J BaselgaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.